p53 Mutation Correlates with Molecular Profile and Outperforms p53 Immunohistochemistry (IHC) in Predicting Response to Neo-Adjuvant Chemotherapy in Operable Early Stage Breast Cancer (ESBC) Conference

Ross, JS, Perou, CM, Slodkowska, E et al. (2009). p53 Mutation Correlates with Molecular Profile and Outperforms p53 Immunohistochemistry (IHC) in Predicting Response to Neo-Adjuvant Chemotherapy in Operable Early Stage Breast Cancer (ESBC) . LABORATORY INVESTIGATION, 89 66A-66A.

cited authors

  • Ross, JS; Perou, CM; Slodkowska, E; Ross, MS; Boguniewicz, AB; McKenna, EF; Lawrence, HJ; Royce, M; Gluck, S

authors

date/time interval

  • March 7, 2009 -

publication date

  • January 1, 2009

published in

keywords

  • Life Sciences & Biomedicine
  • Medicine, Research & Experimental
  • Pathology
  • Research & Experimental Medicine
  • Science & Technology

Location

  • MA, Boston

Conference

  • 98th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology

publisher

  • NATURE PUBLISHING GROUP

start page

  • 66A

end page

  • 66A

volume

  • 89